Noraramtide  (Synonyms: BHV-1100)

Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity^[1].

4633.11

C₂₁₀H₃₀₀N₄₈O₆₅S₃

2580150-96-3

Ala-Arg-{2-aminoheptanoicacid}-Tyr-His-Asp-Gly-Val-Leu-{Phe(4-phenyl)}-{2-aminoheptanoicacid}-{d-Cys(s-carboxymethyl)}-{XGly}-{γGlu}-{γGlu}-{d-γGlu}-{γGlu}-{γGlu}-Gly-Gly-Asp-Cys-Ala-Trp-His-Leu-Gly-Glu-Leu-Val-Trp-Cys-Thr (Sulfidebridge:Ala1-Cys13,Disulfidebridge:Cys24-Cys34) X= NH2-PEG6-((6S)-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d][1,2,3]triazol-6-yl)methyl hydrogen carbonate-piperidine-4-carboxylic acid

AR-{2-aminoheptanoicacid}-YHDGVL-{Phe(4-phenyl)}-{2-aminoheptanoicacid}-{d-Cys(s-carboxymethyl)}-{XGly}-{γGlu}-{γGlu}-{d-γGlu}-{γGlu}-{γGlu}-GGDCAWHLGELVWCT (Sulfidebridge: Ala1-Cys13,Disulfidebridge:Cys24-Cys34) X= NH2-PEG6-((6S)-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d][1,2,3]triazol-6-yl)methyl hydrogen carbonate-piperidine-4-carboxylic acid

[Ala-Arg-{2-aminoheptanoicacid}-Tyr-His-Asp-Gly-Val-Leu-{Phe(4-phenyl)}-{2-aminoheptanoicacid}-{d-Cys(s-carboxymethyl)}-{XGly}-{gGlu}-{gGlu}-{d-gGlu}-{gGlu}-{gGlu}-Gly-Gly-Asp-Cys-Ala-Trp-His-Leu-Gly-Glu-Leu-Val-Trp-Cys-Thr (Sulfidebridge:Ala1-Cys13,Disulfidebridge:Cys24-Cys34) X= NH2-PEG6-((6S)-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d][1,2,3]triazol-6-yl)methyl hydrogen carbonate-piperidine-4-carboxylic acid]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Birch G C, et al. Expansion, persistence, and characteristics of autologous, Bhv-1100 armored memory-like NK cells infused prior to autologous stem cell transplant in MRD+ multiple myeloma patients: a first-in-human trial[J]. Blood, 2023, 142: 2105.